Private company

Guardion Health Sciences, Inc.

Guardion Health Sciences, Inc. is an American pharmaceutical preparations company based in Wilmington.2

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersWilmington, United States2
  • Incorporated inDE3
  • Business address2925 Richmond Avenue, Suite 1200, Houston, Tx 770983
  • Filer category, Emerging growth company3
  • Legal formCorporation2
  • LEI5493001V8N461H1N63812
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O THE CORPORATION TRUST COMPANY, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 57768112

See how the biggest companies compare on our leaderboards

Health Sciences, Inc. was formed under the name P4L Health Sciences, LLC in December 2009 in California as a limited liability company.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

44.0%Gross margin6
-35.4%Operating margin6
1.3%Net margin6
10.8%Revenue growth, 20236
1.9%Return on equity6
-$4.4MFree cash flow6

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue56¢$6.9M
  • Research and development1¢$150.7K
  • Other costs42¢$5.1M
  • Profit1¢$158.0K

Out of $12.2M in revenue.6

Financial statements

Revenue78910116$12.2M in 2023+2701% since 2017
0$5.0M$10.0M$15.0M2017: $437.3K$437.3K20172018: $942.2K$942.2K2018+115%2019: $902.9K$902.9K2019−4%2020: $1.9M$1.9M2020+109%2021: $7.2M$7.2M2021+283%2022: $11.0M$11.0M2022+53%2023: $12.2M$12.2M2023+11%
Gross profit78910116$5.4M in 2023+1960% since 2017
-$2.0M0$2.0M$4.0M$6.0M2017: $261.9K$261.9K20172018: $544.0K$544.0K2018+108%2019: $561.6K$561.6K2019+3%2020: -$56.8K-$56.8K20202021: $3.1M$3.1M20212022: $4.5M$4.5M2022+45%2023: $5.4M$5.4M2023+19%
Operating income78910116-$4.3M in 2023−18% since 2017
-$30.0M-$20.0M-$10.0M02017: -$5.3M-$5.3M20172018: -$6.1M-$6.1M2018+16%2019: -$10.5M-$10.5M2019+71%2020: -$8.6M-$8.6M2020−19%2021: -$24.7M-$24.7M2021+189%2022: -$17.4M-$17.4M2022−30%2023: -$4.3M-$4.3M2023−75%
Net income78910116$158.0K in 2023
-$30.0M-$20.0M-$10.0M0$10.0M2017: -$5.3M-$5.3M20172018: -$7.8M-$7.8M2018+46%2019: -$10.9M-$10.9M2019+40%2020: -$8.6M-$8.6M2020−21%2021: -$24.7M-$24.7M2021+189%2022: -$14.9M-$14.9M2022−40%2023: $158.0K$158.0K2023
Fiscal year2017201820192020202120222023
Revenue$437.3K7$942.2K8$902.9K9$1.9M10$7.2M11$11.0M6$12.2M6
Cost of revenue$175.5K7$398.2K8$341.3K9$1.9M10$4.1M11$6.5M6$6.9M6
Gross profit$261.9K7$544.0K8$561.6K9-$56.8K10$3.1M11$4.5M6$5.4M6
Research and development$259.5K7$231.8K8$194.3K9$161.0K10$64.4K11$193.8K6$150.7K6
Operating expenses$27.9M11$21.9M6$9.7M6
Operating income-$5.3M7-$6.1M8-$10.5M9-$8.6M10-$24.7M11-$17.4M6-$4.3M6
Interest$23.7K7$2.3K8$258.4K9$7.3K10
Net income-$5.3M7-$7.8M8-$10.9M9-$8.6M10-$24.7M11-$14.9M6$158.0K6
Earnings per share-$52.2311-$14.156$0.126
Earnings per share (diluted)-$14.156$0.126
Shares (weighted, basic)473.8K shares111.1M shares61.3M shares6
Shares (weighted, diluted)1.1M shares61.3M shares6

Compare Guardion Health Sciences, Inc. with another company

Corporate structure

Guardion Health Sciences, Inc. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Guardion Health Sciences, Inc.

  • Hudson Bay Capital Management LP Filed SC 13G/A on Guardion Health Sciences, Inc., latest Nov 8, 2024 (3 filings since Feb 8, 2023)
  • Radoff Bradley Louis Filed SC 13G/A on Guardion Health Sciences, Inc., latest Aug 28, 2024 (3 filings since Nov 30, 2022)
  • GREAT POINT CAPITAL LLC Filed SCHEDULE 13G/A on Guardion Health Sciences, Inc., latest May 23, 2024
  • INTRACOASTAL CAPITAL, LLC Filed SC 13G/A on Guardion Health Sciences, Inc., latest Feb 6, 2024 (3 filings since Feb 28, 2022)
  • Guardion Health Sciences, Inc. Wilmington, Delaware, United States
    • NutriGuard Formulations, Inc. Subsidiary · Delaware, United States
    • Viactiv Nutrititionals, Inc. Subsidiary · Delaware, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Guardion Health Sciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$179.9K6 Dec 31, 2023$176.1K6 Dec 31, 2022+2.2%
Accumulated depreciation$146.7K6 Dec 31, 2023$127.3K6 Dec 31, 2022+15.3%
Property and equipment, net$33.2K6 Dec 31, 2023$48.9K6 Dec 31, 2022−32.0%
Operating-lease assets (leased space)$24.3K6 Dec 31, 2022$24.3K11 Dec 31, 20210%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$6.4M6 Dec 31, 2023$10.7M6 Dec 31, 2022−40.3%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$06 Dec 31, 2023$11.3M11 Dec 31, 2021−100.0%
Patents, net$50.7K6 Dec 31, 2023$61.2K6 Dec 31, 2022−17.2%

Inventory

ItemLatestA year beforeChange
Inventory, total$2.7M6 Dec 31, 2023$3.1M6 Dec 31, 2022−14.2%
Raw materials$35.4K6 Dec 31, 2023$49.6K6 Dec 31, 2022−28.7%

Leadership

Who has led Guardion Health Sciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Michael Favish2016–2019
  2. Bret Scholtes2021–2022

Chair

  1. Michael Favish2016–2017

President

  1. Bret Scholtes2021–2022

Chief financial officer

  1. Andrew C. Schmidt2020
20202025
Board members and other officers (11)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • NutriGuard Formulations, Inc. Delaware4
  • Viactiv Nutrititionals, Inc. Delaware4

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • Guardion Health Sciences, LLCMay 18, 2015 to May 18, 20153

Timeline

  1. Dec 26, 20248-K Executive or director change; Other events28
  2. Nov 18, 20248-K Executive or director change; Bylaws or fiscal year changed29
  3. Oct 31, 20248-K Other events30
  4. Oct 3, 20248-K Listing notice or transfer; Executive or director change31
  5. Sep 23, 20248-K Executive or director change32
  6. Aug 21, 20248-K Other events33
  7. Aug 14, 20248-K Results of operations34
  8. Jul 15, 20248-K Executive or director change35
  9. Jun 6, 20248-K Entered a material agreement; Completed an acquisition or sale; Shareholder vote36
  10. May 23, 20248-K Shareholder vote; Other events37
  11. May 21, 20248-K Other events38
  12. May 15, 20248-K Results of operations; Other events39
  13. Jan 6, 2021New chief executive Bret Scholtes becomes CEO14
  14. Dec 27, 2016New chief executive Michael Favish becomes CEO15
  15. Jun 30, 2015Founded Guardion Health Sciences, Inc. is founded2

Calendar

When it reported results

  1. Aug 14, 2024Reported quarterly or annual results34
  2. May 15, 2024Reported quarterly or annual results39
  3. Apr 1, 2024Reported quarterly or annual results40
  4. Nov 13, 2023Reported quarterly or annual results41
  5. Aug 14, 2023Reported quarterly or annual results42
  6. May 16, 2023Reported quarterly or annual results43
  7. Apr 20, 2023Reported quarterly or annual results44
  8. Nov 14, 2022Reported quarterly or annual results45

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

120 filings to the SEC since October 2021: 5 annual reports, 9 quarterly reports, 47 major events, 19 insider forms, 10 large holders, 30 other. The latest 20:

  1. Jan 24, 2025EFFECT EDGAR
  2. Jan 23, 202515-12G EDGAR
  3. Jan 23, 2025S-8 POS EDGAR
  4. Jan 23, 2025POS AM EDGAR
  5. Dec 26, 20248-K EDGAR
  6. Nov 18, 20248-K EDGAR
  7. Nov 8, 2024SC 13G/A GHSI 13G/A EDGAR
  8. Oct 31, 20248-K EDGAR
  9. Oct 11, 202425 EDGAR
  10. Oct 3, 20248-K EDGAR
  11. Sep 23, 20248-K EDGAR
  12. Aug 28, 20244 OWNERSHIP DOCUMENT EDGAR
  13. Aug 28, 2024SC 13G/A AMENDMENT NO. 2 TO SCHEDULE 13G EDGAR
  14. Aug 21, 20248-K EDGAR
  15. Aug 14, 20248-K EDGAR
  16. Aug 13, 202410-Q EDGAR
  17. Jul 15, 20248-K EDGAR
  18. Jun 6, 20248-K EDGAR
  19. May 23, 2024DEFA14A EDGAR
  20. May 23, 20248-K EDGAR

The 120 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 2 buys and 1 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 26, 2024Radoff Family FoundationSale115,540$14.08$1.6MForm 4
Jan 10, 2023Radoff Family FoundationBuy31,900$7.60$242.3KForm 4
Jan 9, 2023Radoff Family FoundationBuy84,821$6.88$583.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How Guardion Health Sciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARGuardion Health Sciences, Inc.1
  • CIK0001642375
  • Employer ID (EIN)47-44284211
  • Filer status<br>emerging growth company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address2925 Richmond Avenue, Suite 1200, Houston, TX 770981
  • Phone(800) 873-51411
  • Shares outstanding1,284,156 as of Jul 31, 202413
  • Public float$9.9M as of Jun 30, 202350
  • On EDGAR sinceMay 18, 20151
  • Filings373 in all: 8-K (107), 4 (48), 10-Q (23), CORRESP (19), 3 (18), S-1/A (13), UPLOAD (13), EFFECT (10)1
    All 45 form types

    SC 13G/A (9), 10-K (8), 4/A (8), DEFA14A (8), 424B5 (7), D (7), DEF 14A (7), 8-K/A (6), PRE 14A (6), S-1 (6), SC 13D (6), SC 13G (6), 424B4 (3), DRS (3), DRSLTR (3), S-8 (3), 10-K/A (2), 424B3 (2), POS AM (2), RW (2), S-3 (2), 144 (1), 15-12G (1), 25 (1), 425 (1), 8-A12B (1), 8-A12G (1), CERT (1), D/A (1), DEFM14A (1), DEFR14A (1), NT 10-K (1), PREM14A (1), PRER14A (1), S-3/A (1), S-8 POS (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Mar 29, 2024
    Quarterly report (10-Q) Aug 13, 2024
    Proxy statement (DEF 14A) Oct 3, 2023
    Latest 8-K (8-K) Dec 26, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50